



## Revolution Medicines to Participate in March 2025 Investor Conferences

February 24, 2025

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in three upcoming investor conferences.

Details of the company's participation are as follows:

- **TD Cowen 45<sup>th</sup> Annual Healthcare Conference**
  - Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET
- **Barclays 27<sup>th</sup> Annual Global Healthcare Conference**
  - Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET
- **2025 Leerink Partners Global Healthcare Conference**
  - Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET

To listen to a live webcast of any of these events, or access archived webcasts, please visit: <https://ir.revmed.com/events-and-presentations>. Following the live webcasts, replays will be available on the company's website for at least 14 days.

### About Revolution Medicines, Inc.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit [www.revmed.com](http://www.revmed.com) and follow us on [LinkedIn](#).

### Revolution Medicines Media & Investor Contact:

media@revmed.com  
investors@revmed.com